Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Plus Carboplatin in Advanced Urothelial Carcinoma After Enfortumab Vedotin and Pembrolizumab
NCT07043972Phase 2Recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Jul 2025
- Primary completion
- Jan 2030
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, carboplatin in urothelial carcinoma (UC), sponsored by Fox Chase Cancer Center. Started Jul 2025; status: recruiting.
02
Drugs
gemcitabinecarboplatin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07043972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07043972.